Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAHP + AHP
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
TAHP + AHP is not a standard pharmaceutical product or recognized drug combination. Based on available clinical trial data, "TAHP" refers to a regimen used in the treatment of HER2-positive early breast cancer and typically includes trastuzumab (Herceptin), pertuzumab, and chemotherapy agents such as docetaxel and carboplatin. "AHP" in this context refers to an adjuvant phase that may include atezolizumab (an anti-PD-L1 antibody), Herceptin SC (subcutaneous trastuzumab), and pertuzumab[1]. The combination "TAHP + AHP" therefore appears to describe a sequential or combined therapeutic approach involving these agents for HER2-positive breast cancer patients, rather than a single drug entity.
- Other names
- TAHPAHP
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TAHP + AHP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAHP + AHP.